Published in J Cell Physiol on April 01, 2008
Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40
In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor. PLoS One (2013) 0.99
Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer. Front Oncol (2015) 0.91
Widespread gene conversion of alpha-2-fucosyltransferase genes in mammals. J Mol Evol (2009) 0.87
High-density genotyping of immune loci in Kawasaki disease and IVIG treatment response in European-American case-parent trio study. Genes Immun (2014) 0.82
A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody. PLoS One (2009) 0.82
Regulation of glycosyltransferases and Lewis antigens expression by IL-1β and IL-6 in human gastric cancer cells. Glycoconj J (2011) 0.81
Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells. Virchows Arch (2010) 0.79
α(1,2)fucosylation in human colorectal carcinoma. Oncol Lett (2010) 0.77
An easily accessible sulfated saccharide mimetic inhibits in vitro human tumor cell adhesion and angiogenesis of vascular endothelial cells. Beilstein J Org Chem (2012) 0.77
A novel role for inducible Fut2 in angiogenesis. Angiogenesis (2012) 0.76
Fucosylation of LAMP-1 and LAMP-2 by FUT1 correlates with lysosomal positioning and autophagic flux of breast cancer cells. Cell Death Dis (2016) 0.75
Neofunctionalization of the Sec1 α1,2fucosyltransferase paralogue in leporids contributes to glycan polymorphism and resistance to rabbit hemorrhagic disease virus. PLoS Pathog (2015) 0.75
Dynamic regulation of VEGF-inducible genes by an ERK-ERG-p300 transcriptional network. Development (2017) 0.75
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol (2010) 2.66
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 2.25
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol (2004) 2.23
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma (2012) 2.14
Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. Eur Urol (2007) 2.09
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood (2002) 2.00
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood (2005) 1.96
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol (2013) 1.84
Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res (2005) 1.81
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica (2010) 1.80
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res (2010) 1.75
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood (2008) 1.69
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol (2004) 1.67
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol (2010) 1.60
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica (2010) 1.58
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood (2009) 1.51
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis (2003) 1.49
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant (2006) 1.49
Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol (2005) 1.49
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J (2006) 1.48
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene (2005) 1.44
CD200 is a new prognostic factor in multiple myeloma. Blood (2006) 1.44
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol (2007) 1.44
How to treat multiple myeloma - a representative multicentre treatment survey. Onkologie (2010) 1.43
Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma (2008) 1.40
Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer (2008) 1.39
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer (2005) 1.39
Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol (2005) 1.35
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol (2006) 1.35
Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer (2003) 1.34
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood (2012) 1.32
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol (2007) 1.32
Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood (2002) 1.32
CD molecules 2005: human cell differentiation molecules. Blood (2005) 1.27
A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood (2005) 1.27
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood (2013) 1.26
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm (2007) 1.24
Induction of angiogenesis by normal and malignant plasma cells. Blood (2009) 1.22
Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis (2004) 1.20
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood (2004) 1.19
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica (2013) 1.19
A novel serine-rich motif in the intercellular adhesion molecule 3 is critical for its ezrin/radixin/moesin-directed subcellular targeting. J Biol Chem (2002) 1.17
The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood (2007) 1.17
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol (2007) 1.17
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer (2010) 1.16
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol (2006) 1.14
Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant (2009) 1.14
Standardization strategy for quantitative PCR in human seminoma and normal testis. J Biotechnol (2005) 1.13
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant (2011) 1.13
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology (2009) 1.12
A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics (2008) 1.11
High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol (2004) 1.11
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol (2004) 1.10
Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol (2005) 1.09
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica (2008) 1.09
Standardization of Gleason grading among 337 European pathologists. Histopathology (2013) 1.09
Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol (2003) 1.08
IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood (2009) 1.07
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica (2012) 1.07
The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. Int J Cancer (2006) 1.07
Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep (2006) 1.06
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist (2011) 1.06
Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail (2007) 1.05
Mycobacterium kansasii tenosynovitis in a rheumatoid arthritis patient with long-term therapeutic immunosuppression. Arthritis Rheum (2008) 1.05
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica (2012) 1.04
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res (2009) 1.03
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol (2013) 1.03
Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res (2007) 1.03
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol (2008) 1.03